<DOC>
	<DOCNO>NCT02792478</DOCNO>
	<brief_summary>Analysis freely circulate DNA liquid biopsy use BEAMing method</brief_summary>
	<brief_title>Determination RAS Mutation Status Liquid Biopsies Subjects With RAS Wild-type.PERSEIDA Study</brief_title>
	<detailed_description>Analysis freely circulate DNA liquid biopsy use BEAMing method propose technique may useful analyse RAS mutation status different type cancer . However , first necessary evaluate concordance result obtain tumour sample liquid biopsy . Primary objective â€¢ To evaluate RAS mutation status baseline liquid biopsy subject RAS wild-type metastatic colorectal cancer . Secondary objective - To evaluate appearance new RAS mutation use liquid biopsy moment disease progression . - To evaluate appearance new RAS mutation use liquid biopsy prior radiological documentation disease progression .</detailed_description>
	<criteria>Inclusion criterion : Subjects give informed consent write Subjects metastatic colorectal cancer , measurable RECIST , start firstline treatment Male female subject , least 18 year age ethnicity Subjects histologicallyconfirmed diagnosis colorectal carcinoma metastatic disease wildtype RAS . Exclusion criterion : Pregnant breastfeed woman Subjects previously receive monoclonal antibody EGFR ( cetuximab panitumumab ) , smallmolecule EGFR inhibitor ( erlotinib ) biological cancer treatment History another solid haematological tumour previous 5 year , except history basal cell carcinoma skin preinvasive cervical cancer Subjects participate participate clinical trial 30 day prior inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>